MedTrace Logo

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

NCT05335122 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2025-03-21

No results posted yet for this study

Summary

To assess efficacy, and safety of a single sustained release dose of the OTX-TIC drug product (2 travoprost dose strengths) in subjects with Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Conditions

Interventions

DRUG

OTX-TIC low dose Travoprost Intracameral Implant

OTX-TIC implant is injected into the anterior chamber of the eye.

DRUG

OTX-TIC high dose Travoprost Intracameral Implant

OTX-TIC implant is injected into the anterior chamber of the eye.

DRUG

Durysta, Bimatoprost Intracameral Implant 10 µg

Durysta is injected into the anterior chamber of the eye.

Sponsors & Collaborators

  • Ocular Therapeutix, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-16
Primary Completion
2024-01-24
Completion
2025-01-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05335122 on ClinicalTrials.gov